secwatch / observer

8-K filed September 3, 2024, 7:59 PM ET ticker RXRX CIK 0001601830

other material confidence medium sentiment neutral materiality 0.75

Recursion reports top-line SYCAMORE data, files Exscientia financials for proposed merger

RECURSION PHARMACEUTICALS, INC.

SYCAMORE Phase 2 trial for REC-994 in symptomatic CCM patients: top-line results announced Sept 3, 2024 (press release as Exhibit 99.2).
Filed audited financials of Exscientia for FY2023 and FY2022 (Exhibit 99.3) and unaudited interim statements for H1 2024 (Exhibit 99.4).
Filed pro forma condensed combined balance sheet as of June 30, 2024 and pro forma statements of operations (Exhibit 99.5).
Transaction closing deadline Aug 8, 2025; termination fees: Recursion $58.77M, Exscientia $6.88M; subject to HSR, court, stockholder votes.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001601830-24-000148
form_type: 8-K
ticker: RXRX
cik: 0001601830
company_name: RECURSION PHARMACEUTICALS, INC.
filed_at: 2024-09-03T23:59:59+00:00
discovered_at: 2026-05-14T18:03:13.723638+00:00
generated_at: 2026-05-31T06:37:40.824031+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: medium
secwatch_canonical_url: https://secwatch.observer/filing/0001601830-24-000148
json_url: https://secwatch.observer/filing/0001601830-24-000148.json
markdown_url: https://secwatch.observer/filing/0001601830-24-000148.md
text_url: https://secwatch.observer/filing/0001601830-24-000148.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000148/0001601830-24-000148-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000148/rxrx-20240903.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

TRTX

TRTX posts 1Q26 distributable earnings $0.25/sh, book value $11.06, loan portfolio $4.3B

TPG RE Finance Trust, Inc. June 1, 2026, 5:23 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001601830-24-000148

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.